Clinical Features and Genetic Findings of Autosomal Recessive Bestrophinopathy

Hae Rang Kim 1,2, Jinu Han 3, Yong Joon Kim 1, Hyun Goo Kang 1, Suk Ho Byeon 1, Sung Soo Kim 1 and Christopher Seungkyu Lee 1,*

1 Department of Ophthalmology, Institute of Vision Research, Yonsei University College of Medicine, Seoul 03722, Korea; khr1412@chamc.co.kr (H.R.K.); kyjcolor@naver.com (Y.J.K.); hgkang08@yuhs.ac (H.G.K.); shbyeon@yuhs.ac (S.H.B.); semekim@yuhs.ac (S.S.K.)
2 Department of Ophthalmology, CHA Bundang Medical Center, CHA University College of Medicine, Seongnam 13496, Korea
3 Department of Ophthalmology, Institute of Vision Research, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea; jinuhan@yuhs.ac
* Correspondence: sklee219@yuhs.ac; Tel.: +82-2-2228-3570; Fax: +82-2-312-0541

Abstract: Autosomal recessive bestrophinopathy (ARB) is a rare subtype of bestrophinopathy caused by biallelic mutations of the BEST1 gene. ARB is characterized by multifocal subretinal deposits accompanied by macular edema or subretinal fluid, hyperopia, co-existing narrow angle, and a marked decrease in electrooculogram. However, little is known about the genetic variants and specific clinical features of ARB. This is an observational case series of patients with a clinical and genetic diagnosis of ARB who underwent multimodal imaging. We describe ten patients from nine unrelated families with six known variants and three novel missense variants: c.236C→T, p.(Ser79Phe); C.452C→T, p.(Leu151Pro); and c.650C→T, p.(Trp217Met). The most common variant was c.584C→T, p.(Ala195Val), observed in six patients, without correlation to the severity of the phenotype. All patients manifested bilateral multifocal subretinal deposits and subretinal fluid throughout the follow-up period, while intraretinal fluid was found in approximately half of the eyes. The extent or chronicity of the fluid collection did not correlate with visual acuity. Angle-closure glaucoma was present in five eyes. Three patients had a genetically confirmed family history of ARB, and one patient had a clinically suspected family history. This study reveals novel mutations in the BEST1 gene and adds to the spectrum of clinical presentations of ARB.

Keywords: autosomal recessive bestrophinopathy (ARB); BEST1 gene

1. Introduction

Bestrophinopathy is a spectrum of inherited macular degenerations caused by mutations in the BEST1 gene [1]. BEST1 is located on chromosome 11q13 [2,3] and encodes bestrophin-1, a 585 amino-acid calcium-activated Cl− channel localized to the basolateral membrane of retinal pigment epithelium (RPE) [4]. Mutation in the BEST1 gene might result in abnormal functioning of the protein bestrophin-1, an anion channel in the RPE, leading to a variety of retinopathies [5,6]. The most prevalent variant, Best vitelliform macular dystrophy [VMD, also known as Best disease; Online Mendelian Inheritance in Man identifier (OMIM), 153700], is characterized by prominent central macular lesions that undergo consecutive morphologic changes from characteristic ‘egg-yolk’ appearance in the vitelliform stage to vitelliruptive stage, pseudohypopion state, and atrophic stage [7]. Since the first report in 1905 by Friedrich, a wide array of missense mutations in BEST1 variants have been reported [8]. Other subtypes include adult-onset vitelliform macular dystrophy (OMIM 153840), autosomal dominant vitreoretinchoroidopathy (OMIM 193220), retinitis pigmentosa 50 (OMIM 613194), and autosomal recessive bestrophinopathy (OMIM 611809) [7].
In 2006, Schatz et al. first reported two related patients with multifocal vitelliform dystrophy and compound heterozygous BEST1 variants. Burgess et al. then denominated the term “autosomal recessive bestrophinopathy” (ARB) as a new BEST1-associated phenotype. Unlike missense mutations in autosomal dominant inheritance of VMD, ARB is caused by a homozygous or compound heterozygous BEST1 mutation with a modifier effect of the first on the second mutation in the latter [9,10]. ARB is characterized by multifocal diffuse subretinal deposits that appear hyperfluorescent on fundus autofluorescence imaging, accompanied by macular edema or subretinal fluid, hyperopia, and co-existing narrow angle. Electrophysiological characteristics include a marked decrease in light rise on electrooculography (EOG) and relatively preserved electoretinography (ERG) parameters unless photoreceptor cells are severely damaged. Although abnormal EOG findings are crucial for the diagnosis of bestrophinopathy, mutation analysis is necessary to confirm the diagnosis of a specific subtype of bestrophinopathy.

The prevalence of ARB is estimated to be 1/1,000,000 [9]. In Korea, only two patients with ARB from a single family were reported in 2015 [11]. Herein, we report on ten patients with ARB due to mutations in BEST1, characterizing their clinical features and genetic mutations.

2. Materials and Methods

2.1. Study Design and Subjects

In this retrospective cohort study, we reviewed medical records of patients with clinical features of ARB who were followed up at the Department of Ophthalmology of two tertiary referral hospitals in Korea (Severance Eye Hospital and Gangnam Severance Hospital, Yonsei University Medical Center, Seoul) between November 2009 and December 2021. Typical clinical characteristics of ARB include bilateral multifocal vitelliform lesions that appear hyperfluorescent on autofluorescence imaging with or without intraretinal fluid (IRF) or subretinal fluid (SRF). The final diagnosis of ARB was confirmed using genomic data generated by next-generation sequencing (NGS). We excluded three patients without genetic information and one patient with poor image quality who was lost to follow-up.

The study was conducted in accordance with the Declaration of Helsinki and the protocol was approved by the Institutional Review Board (IRB) of Yonsei University Medical Center (IRB approval number: 2022-1285-001). The requirement for informed consent was waived because this study used only anonymized data before the analysis.

2.2. Data Collection

Data regarding demographic characteristics (age and sex), duration of symptoms (interval between the reported onset of visual symptoms and diagnosis of ARB), and family history of ocular disease were collected for each patient. For each affected eye, the best-corrected visual acuity (BCVA), refraction, intraocular pressure, slit-lamp and dilated fundoscopy results, presence of ocular comorbidities, and previous treatments before the initial visit were recorded. Medical therapy included intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections and laser photocoagulation treatment.

2.3. Ophthalmologic Image Interpretation

Ophthalmologic paraclinical examination findings were assessed by two retinal specialists (H.R.K. and Y.J.K.). Multimodal imaging, including color fundus photography, widefield retinal imaging, spectral-domain optical coherence tomography (OCT; Heidelberg Engineering, Heidelberg, Germany), autofluorescence (AF) imaging at the initial presentation and the latest follow-up visit were reviewed. ERG and EOG data were collected if available.

Vitelliform lesions were defined as well-demarcated yellow subretinal deposits confirmed by color fundus photography and OCT, which appeared hyperautofluorescent on AF images. The presence of IRF (defined as >3 adjacent intraretinal hyporeflective spaces visible on OCT), SRF, and pigment epithelium detachment was evaluated. The extent
of SRF was categorized as diffuse if the fluid involved the entire line scan on the OCT B-scan, subfoveal if limited to the juxtafoveal area, or absent. Central retinal thickness (CRT) and subfoveal choroidal thickness (CT) from the central 1-mm subfield were determined manually using the built-in caliper of the Heidelberg software. Outer retinal layer thickening, a thicker layer of the interdigitation zone between the RPE and the ellipsoid zone interface, was also examined. Finally, focal choroidal excavation (FCE) was defined as an area of concavity in the choroid without scleral ectasia or posterior staphyloma detected on OCT [12]. Where available, widefield retinal images were graded for the presence of peripheral drusen-like material, defined as the accumulation of subretinal deposits without a decreased AF signal and the presence of RPE atrophy.

2.4. Genetic Analysis

For patients with clinical features of ARB, informed consent for genetic analysis was obtained before DNA testing. For the customized NGS panel, genomic DNA samples extracted from peripheral blood leukocytes according to established protocols were evaluated for causative genes of ARB based on literature reviews, RetNet database (http://sph.uth.edu/Retnet/ accessed on 4 June 2022), and OMIM database (http://www.ncbi.nlm.nih.gov/omim accessed on 4 June 2022). Target enrichment was performed using a customized target enrichment kit (Celemics Inc., Seoul, Korea). Sequencing and bioinformatics analyses were performed as previously described [13]. Briefly, the pooled libraries were sequenced using a NextSeq 550 sequencer (Illumina, San Diego, CA, USA) and the NextSeq Reagent Kit, version 2 (300 cycles). A final diagnosis of ARB was made when compound heterozygous variants in the \textit{BEST1} gene were confirmed, only including variants with “pathologic”, “likely pathologic”, or “uncertain significance” qualifiers among the five-tier classification system. Patients with inconclusive genetic data were excluded from the study, even those with typical ARB phenotypes.

3. Results

Ten patients from nine unrelated families were included in the study. Patient characteristics are summarized in Table 1. The mean age at onset of subjective symptoms and at diagnosis was 25.8 ± 13.4 (range, 6–50) years and 34.8 ± 18.8 (range, 6–67) years, respectively. Eight (80%) patients complained of reduced central vision as the initial symptom, while two (20%) patients (patients 4 and 10) were asymptomatic. At the final visit, three patients (patients 6, 8, and 10) subjectively reported gradual decline in vision while others claimed no vision change. The median initial BCVA of the right and left eye were 0.47 (range, 0.025–1.0) and 0.52 (range, 0.025–1.0), respectively. The median final BCVA of the right eye and left eye were 0.39 (range, 0.04–1.0) and 0.42 (range, 0.04–1.0), respectively. There was no significant difference between initial and final BCVA in both eyes ($p = 0.604$ for the right eye; $p = 0.630$ for the left eye). One (10%) patient (patient 5) presented with concurrent retinal vein occlusion in the left eye, which was resolved with successive intravitreal bevacizumab injections. Nine (45%) eyes of ten patients were hyperopic, and five (25%) eyes of three patients were diagnosed with angle-closure glaucoma.

All patients manifested bilateral multifocal vitelliform lesions on fundus photography with fovea-involving SRF and/or IRF on OCT B-scans (Figure S1). In addition, fundus autofluorescence imaging revealed marked hyperautofluorescence corresponding to yellow vitelliform lesions (Figure 1). The extent of vitelliform lesions was relatively consistent in all patients throughout the follow-up period, showing no correlation to BCVA. Subtle extramacular hyperautofluorescent deposits were often observed. Five (25%) eyes of three patients presented with peripheral drusen-like deposits, presumed to be located at the subretina [14], which appeared hypofluorescent on AF images (Figure 2).
Table 1. Baseline characteristics.

| Patient No. | Sex | Age at Onset (Year) | Age at Diagnosis (Year) | Follow-Up Period (Months) | Visual Acuity * at Initial Visit | Visual Acuity * at Final Visit | Spherical Equivalent | Primary Angle-Closure Glaucoma | Family History |
|-------------|-----|---------------------|-------------------------|---------------------------|-------------------------------|-------------------------------|---------------------|-----------------------------|----------------|
| 1           | F   | 33                  | 35                      | 52                        | 0.15                          | 0.15                          | −2.13               | Yes                         | Yes (brother) |
| 2           | M   | 30                  | 33                      | 11                        | 1.0                           | 1.0                           | −1.50               | No                          | No             |
| 3           | M   | 10                  | 16                      | 14                        | 1.0                           | 1.0                           | 1.50                | No                          | No             |
| 4           | F   | 32                  | 32                      | 44                        | 0.7                           | 0.5                           | −1.00               | Yes                        | No             |
| 5           | F   | 20                  | 53                      | 105                       | 0.025                         | 0.025                         | 4.25                | No                          | Yes (brother) |
| 6           | M   | 25                  | 67                      | 145                       | 0.1                           | 0.1                           | 2.75                | No                          | Yes (Sister) |
| 7           | F   | 37                  | 39                      | 21                        | 0.5                           | 0.4                           | −0.63               | No                          | No             |
| 8           | F   | 50                  | 51                      | 10                        | 0.2                           | 0.2                           | −0.50               | No                          | Suspected (Sister) |
| 9           | M   | 15                  | 16                      | 12                        | 0.3                           | 0.3                           | −1.00               | No                          | No             |
| 10          | F   | 6                   | 6                       | 14                        | 0.7                           | 0.8                           | 2.63                | No                          | No             |

Abbreviations: OD, right eye; OS, left eye; F, female; M, male. * Snellen visual acuity.

Figure 1. Multimodal retinal imaging of patient 7, a 37-year-old female with p.Ala195Val and p.Arg255Trp mutation in BEST1. At the initial visit, best corrected Snellen visual acuity was 0.5 for the right eye and 0.8 for the left eye, while the patient complained of subjective vision decrease only in the right eye despite the maculopathy in both eyes. (A,B) Widefield color images show bilateral multifocal vitelliform lesions. (C,D) Fluorescein angiography show non-specific hyperfluorescence. (E,F) Fundus photography clearly showing vitelliform lesions (white asterisks) in the posterior pole that topographically correspond to an increase in autofluorescence intensity (black asterisks) in 55° fundus autofluorescence images (G,H). (I,J) Spectral-domain optical coherence tomography B-scans also show subretinal hyperreflective deposits (red asterisks), subretinal fluid, and outer retinal layer thickening in both eyes.
Figure 2. Widefield images of a 33-year-old man (patient 2, p.Arg255Trp and p.Ser79Phe mutation in BEST1). (A,B) Peripheral drusen-like materials (white arrows), presumed subretinal, are visible in widefield imaging, and appear hypofluorescent on widefield autofluorescence imaging (C,D). No evident peripheral retinal pigment epithelium atrophy was found.

OCT analysis revealed the presence of either SRF or IRF in both eyes of all the patients at the initial and final visits. Specifically, SRF was consistently sustained in all eyes during the follow-up period, whereas IRF was found in 11 (55%) eyes at the initial visit and in 9 (45%) eyes at the final visit. One patient (patient 8) received intravitreal bevacizumab injections due to misdiagnosis of chronic central serous chorioretinopathy, which was not effective in resolving the retinal fluid. One patient (patient 7) exhibited an increase in SRF and a newly developed IRF at the final visit without visual impairment. The extent or chronicity of the fluid did not correlate with BCVA. The CRT appeared to become progressively thinner, but there was no statistically significant difference between the initial and final values (Table 2). There was no significant change in the subfoveal CT during follow-up. Outer retinal layer thickening was found in 14 (70%) eyes of seven patients throughout the follow-up period, while the inner retinal layer remained relatively intact in the parafoveal areas.

One patient (patient 9) showed FCE in both eyes at the initial examination (Figure 3). Irregular PED (retinal pigment epithelial detachment) with subretinal hyperreflective materials was also found, indicating the possibility of an association with relatively indolent type 2 neovascular lesions [14].
Table 2. Spectral-domain optical coherence tomography parameters of 20 eyes with autosomal recessive bestrophinopathy at initial and final visits.

| OCT Parameters                          | At Initial Visit | At Final Visit |
|----------------------------------------|-----------------|---------------|
| Macular subretinal deposit (%)         |                 |               |
| Unifocal                               | 30              | 25            |
| Multifocal                             | 60              | 60            |
| Subretinal fluid (%)                   |                 |               |
| Sub-foveal                             | 70              | 60            |
| Diffuse                                | 10              | 20            |
| Intraretinal fluid (%)                 | 50              | 40            |
| Focal choroidal excavation (%)         | 10              | 10            |
| Central macular thickness (µm) *       | 198.8 ± 231.2/173.7 ± 167.4 | 185.9 ± 196.3/153.9 ± 150.7 |
| Subfoveal choroidal thickness (µm) *   | 303.4 ± 70.5/280.4 ± 76.7 | 289.3 ± 61.9/286.5 ± 47.4 |
| Outer retinal layer thickening (%)     | 70              | 70            |

Abbreviations: OCT, optical coherence tomography. * Presented as right eye/left eye. Data are shown as mean ± standard deviation.

Figure 3. Focal choroidal excavation in both eyes of a 16-year-old male (patient 9, p.Arg47His and p.Ile38Ser mutation in BEST1) (A,B) Large juxtafoveal subretinal deposits with surrounding small deposits are present in both eyes. (C,D) The location of subretinal vitelliform material (black asterisks) topographically overlay the focal choroidal excavation (red arrows), challenging the detection of possible choroidal neovascularization at focal choroidal excavation.

All subjects harbored compound heterozygous mutations in the BEST1 gene (Table 3). Nine unique disease-associated variants, including three novel mutations, have been reported. The most common mutation was c.584C→T, p.(Ala195Val), detected in six unrelated patients (patients 3, 5, 6, 7, 8, and 10). Patients 5 and 6 were siblings of the same pedigree, as previously reported [11]. Three missense mutations with uncertain significance included c.236C→T, p.(Ser79Phe), c.452C→T, p.(Leu151Pro), and c.650C→T, p.(Trp217Met).
Table 3. List of BEST1 mutation variants and predicted effects.

| Patient No. | BEST1 Mutation | Amino Acid Change | BEST1 Mutation | Amino Acid Change |
|-------------|----------------|-------------------|----------------|-------------------|
| 1           | c.763C>T       | p.Arg255Trp       | c.113T>G       | p.Ile38Ser        |
| 2           | c.763C>T       | p.Arg255Trp       | c.236C>T       | p.Ser79Phe        |
| 3           | c.584C>T       | p.Ala195Val       | c.763C>T       | p.Arg255Trp       |
| 4           | c.452C>T       | p.Leu151Pro       | c.650C>T       | p.Trp217Met       |
| 5           | c.119T>C       | p.Leu40Pro        | c.584C>T       | p.Ala195Val       |
| 6           | c.119T>C       | p.Leu40Pro        | c.584C>T       | p.Ala195Val       |
| 7           | c.584C>T       | p.Ala195Val       | c.763C>T       | p.Arg255Trp       |
| 8           | c.584C>T       | p.Ala195Val       | c.763C>T       | p.Arg255Trp       |
| 9           | c.140G>A       | p.Arg47His        | c.113T>G       | p.Ile38Ser        |
| 10          | c.584C>T       | p.Ala195Val       | c.632T>C       | p.Leu211Pro       |

Electrophysiological studies reflected impaired function of RPE and photoreceptor cells in both eyes almost symmetrically (Table 4). Twelve (60%) eyes of eight patients showed a prominent decrease or absence of a light peak, while the others showed subnormal Arden ratios in EOG. The ERG results were mostly within normal limits, except for two patients (patients 5 and 6). Both patients showed prominent thinning of the fovea and disruption of the inner segment/outer segment junction layer at the fovea, possibly due to chronic progressive destruction of macular function over 20 years.

Table 4. Electrophysiologic study of patients.

| Patient No. | ERG            | EOG (Arden Ratio) |
|-------------|----------------|-------------------|
|             | OD  | OS  | OD  | OS  |
| 1           | WNL | WNL | 1.1 | 1.8 |
| 2           | WNL | WNL | 1.9 | 1.4 |
| 3           | WNL | WNL | 1.8 | 1.5 |
| 4           | WNL | WNL | 1   | 1   |
| 5           | Rod and cone impairment | 1.5 | 2 |
| 6           | Rod and cone impairment | 0.92 | 1.06 |
| 7           | Not performed | Not performed |
| 8           | Not performed | Not performed |
| 9           | WNL | WNL | 1.1 | 1 |
| 10          | Not performed | 1.5 | 1.1 |

Abbreviations: ERG, electroretinogram; EOG, electrooculogram; OD, right eye; OS, left eye; WNL, within normal limits.

4. Discussion

BEST1 mutations have long been thought to act solely in an autosomal dominant manner. In 2008, Burgess et al. first defined autosomal recessive disease with BEST1 mutation as a distinct category of bestrophinopathy, termed ARB [7]. Nearly 40 biallelic mutations in BEST1 have been reported in patients with ARB to date [15–17]. Retinopathy in ARB includes irregularly distributed yellow deposits throughout the posterior fundus, which can be easily detected on autofluorescence imaging. Retinal edema and SRF are common findings in OCT imaging. ARB is associated with markedly abnormal EOG and relatively preserved ERG findings. Finally, the presence of compound heterozygous mutations in the BEST1 gene is conclusive in the final diagnosis due to the diverse phenotypes of ARB and overlapping clinical features of bestrophinopathy spectrum diseases.

Burgess et al. speculated that ARB is the human null phenotype for the BEST1 gene [10], which results from a complete loss of bestrophin-1 protein function within the RPE. Therefore, it was suggested that the autosomal recessive phenotype only manifests when bestrophin-1 activity drops below a functional threshold [10]. However, Li et al. suggested that partial loss-of-function mutations in the BEST1 can also cause ARB, which presents less severe clinical features compared to null mutations [18]. As such, the initial presentation of the disease may be nonspecific or even asymptomatic due to incomplete
penetrance. This may explain the lack of subjective symptoms and slow progressive decrease in central vision in our cohort. ARB has a wide age of onset, ranging from childhood to late adulthood. This trend can also be seen in our study, where disease onset ranged from the first to the sixth decade of life.

In this report, we analyzed the genetic and clinical characteristics of ten patients with ARB from nine unrelated families. Nine variants in BEST1 were detected, including three novel mutations. Missense mutation was the only type of mutation detected in this cohort and it has been previously reported to be the most common type [19]. Despite being one of the most common retinal disorders caused by RPE mutations, a wide spectrum of bestrophinopathies are currently untreatable. Additionally, several cases of recessively inherited Best vitelliform macular dystrophy phenotype have been reported [20,21]. A simple dichotomy in inheritance patterns might lead to an inaccurate diagnosis of bestrophinopathies. Therefore, further studies are warranted to connect the functionality of the BEST1 channel to the pathogenesis and progression of bestrophinopathies. Familial genetic studies in patients with novel mutations (c.236C→T in patient 2 and c.452C→T and c.650C→T in patient 4) might broaden our understanding of this disease entity.

Mutations in the BEST1 gene cause abnormal functioning of bestrophin-1, \( \text{Ca}^{2+} \)-activated \( \text{Cl}^{-} \) channels in the RPE, that are thought to generate EOG signals [6]. In electrophysiological studies, all patients showed abnormal EOG findings, suggesting a primary defect localized to the RPE. This explains the prevalent manifestation of SRF or IRF at the initial presentation due to dysfunction of the subfoveal or juxtafoveal RPE. However, central vision was relatively preserved as long as a certain amount of photoreceptor cells (outer retinal layer) were preserved, regardless of a profound amount of SRF and/or IRF at the fovea. Morphological OCT results indicated abnormal photoreceptor structure but unchanged inner retinal layers associated with abnormal cone responses in the central retina. However, bright flash ERG stimulates central and peripheral retina simultaneously, and ERG results indicate only global rod and cone photoreceptor function [15]. Therefore, the ERG results were mostly within normal limits, except for patients with profound disruption of photoreceptor cells or inner retina. The preservation of the inner retina and relatively normal ERG at an earlier stage demonstrate that early recognition and potential treatment at this stage might be a critical endpoint of prognosis in the future.

Additionally, patients with betrophinopathies are at a risk of choroidal neovascularization. Large vitelliform lesions often hinder the detection of underlying neovascular membranes [22]. Several reports have pointed out favorable outcomes with the use of anti-VEGF therapy when choroidal neovascularization is present [22,23]. However, anti-VEGF injections for SRF/IRF in the absence of choroidal neovascularization appear to be ineffective in ARB. The distribution of SRF or IRF depends on the residual function of the RPE and not on the neovascular factors. In addition, the presence of SRF or IRF did not significantly interfere with the visual acuity. The use of anti-VEGF agents should be decided cautiously with the aid of fluorescence angiography, indocyanine green angiography, or OCT angiography.

Our study has several limitations. The design of the study was retrospective and observational. Follow-up periods varied among patients which may have affected the analysis on clinical outcomes. Also, electrophysiological data was unavailable in some patients. Finally, only small number of subjects from a single ethnicity (Korean) were included in this study. Further studies on larger number of subjects from diverse ethnicity are warranted.

5. Conclusions

In conclusion, our study adds to the spectrum of clinical presentations caused by compound heterozygous mutations in the BEST1 gene. Nevertheless, further studies are needed on the genetic analysis of the family of patients, as well as other patients with atypical forms of ARB. Multimodal imaging including wide-field fundus photography, autofluorescence, OCT, and EOG can be helpful in visualizing retinal abnormalities of
clinically suspected ARB; however, genetic verification is recommended to confirm the diagnosis. Understanding the genetics and pathophysiology of bestrophinopathies may be useful to predict the prognosis and develop potential gene therapy in the future.

Supplementary Materials: The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/genes13071197/s1, Figure S1: Ocular characteristics of patients at initial visit. From left to right: fundus photographs, fundus autofluorescence images, and spectral-domain optical coherence tomography.

Author Contributions: Conceptualization, C.S.L.; Methodology, H.R.K. and C.S.L.; Validation, J.H. and C.S.L.; Data curation, H.R.K., Y.J.K., H.G.K. and S.S.K.; Formal analysis, H.R.K. and Y.J.K.; Writing—original draft, H.R.K., Y.J.K. and H.G.K.; Writing—review and editing, S.H.B., S.S.K., J.H. and C.S.L.; Supervision, J.H. and C.S.L.; Funding acquisition, C.S.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF) under 2019R1A2C2002393 (C.S.L.). The funding organization had no role in the design or conduct of this study.

Institutional Review Board Statement: The study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Severance Hospital (2022-1285-001).

Informed Consent Statement: Written informed consent has been obtained from the patients for the publication of this paper.

Data Availability Statement: Data presented in this study is contained within the article.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Lee, J.H.; Oh, J.O.; Lee, C.S. Induced Pluripotent Stem Cell Modeling of Best Disease and Autosomal Recessive Bestrophinopathy. *Yonsei Med. J.* 2020, 61, 816–825. [CrossRef] [PubMed]
2. Forsman, K.; Graff, C.; Nordström, S.; Johansson, K.; Westermark, E.; Lundgren, E.; Gustavson, K.H.; Wadelius, C.; Holmgren, G. The gene for Best’s macular dystrophy is located at 11q13 in a Swedish family. *Clin. Genet.* 1992, 42, 156–159. [CrossRef] [PubMed]
3. Stone, E.M.; Nichols, B.E.; Streb, L.M.; Kimura, A.E.; Sheffield, V.C. Genetic linkage of vitelliform macular degeneration (Best’s disease) to chromosome 11q13. *Nat. Genet.* 1992, 1, 246–250. [CrossRef] [PubMed]
4. Marmorstein, A.D.; Marmorstein, L.Y.; Rayborn, M.; Wang, X.; Hollyfield, J.G.; Petrukhin, K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. *Proc. Natl. Acad. Sci. USA* 2000, 97, 12758–12763. [CrossRef] [PubMed]
5. Yang, T.; Justus, S.; Li, Y.; Tsang, S.H. BEST1: The Best Target for Gene and Cell Therapies. *Mol. Ther.* 2015, 23, 1805–1809. [CrossRef] [PubMed]
6. Xiao, Q.; Hartzell, H.C.; Yu, K. Bestrophins and retinopathies. *Pfugers Arch.* 2010, 460, 559–569. [CrossRef] [PubMed]
7. Boon, C.J.; Klevering, B.J.; Leroy, B.P.; Hoyn, C.B.; Keunen, J.E.; den Hollander, A.I. The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. *Prog. Retin Eye Res.* 2009, 28, 187–205. [CrossRef] [PubMed]
8. Best, F., II. Über eine hereditäre Maculaaflektion. *Ophthalmologica* 1905, 13, 199–212. [CrossRef] [PubMed]
9. Habibi, I.; Falfoul, Y.; Todorova, M.G.; Wysrch, S.; Vaclavik, V.; Helfenstein, M.; Turki, A.; Matri, K.E.; Matri, L.E.; Schorderet, D.F. Clinical and Genetic Findings of Autosomal Recessive Bestrophinopathy (ARB). *Genes* 2019, 10, 953. [CrossRef]
10. Burgess, R.; Millar, I.D.; Leroy, B.P.; Urquhart, J.E.; Fearon, I.M.; De Baere, E.; Brown, P.D.; Robson, A.G.; Wright, G.A.; Kestelyn, P.; et al. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. *Am. J. Hum. Genet.* 2008, 82, 19–31. [CrossRef] [PubMed]
11. Lee, C.S.; Jun, I.; Choi, S.I.; Lee, J.H.; Lee, M.G.; Lee, S.C.; Kim, E.K. A Novel BEST1 Mutation in Autosomal Recessive Bestrophinopathy. *Investig. Ophthalmol. Vis. Sci.* 2015, 56, 8141–8150. [CrossRef] [PubMed]
12. Kim, H.; Woo, S.J.; Kim, Y.K.; Lee, S.C.; Lee, C.S. Focal Choroidal Excavation in Multifocal Choroiditis and Punctate Inner Choroidopathy. *Ophthalmology* 2015, 122, 1534–1535. [CrossRef] [PubMed]
13. Rim, J.H.; Lee, S.T.; Gee, H.Y.; Lee, B.J.; Choi, J.R.; Park, H.W.; Han, S.H.; Han, J. Accuracy of Next-Generation Sequencing for Molecular Diagnosis in Patients With Infantile Nystagmus Syndrome. *JAMA Ophthalmol.* 2017, 135, 1376–1385. [CrossRef] [PubMed]
14. Casalino, G.; Khan, K.N.; Armengol, M.; Wright, G.; Pontikos, N.; Georgiou, M.; Webster, A.R.; Robson, A.G.; Grewal, P.S.; Michaelides, M. Autosomal Recessive Bestrophinopathy: Clinical Features, Natural History, and Genetic Findings in Preparation for Clinical Trials. Ophthalmology 2021, 128, 706–718. [CrossRef]

15. Gerth, C.; Zawadzki, R.J.; Werner, J.S.; Héon, E. Detailed analysis of retinal function and morphology in a patient with autosomal recessive bestrophinopathy (ARB). Doc. Ophthalmol. 2009, 118, 239–246. [CrossRef]

16. Wittström, E.; Ekvall, S.; Schatz, P.; Bondeson, M.L.; Ponjavic, V.; Andréasson, S. Morphological and functional changes in multifocal vitelliform retinopathy and biallelic mutations in BEST1. Ophthalmol. Genet. 2011, 32, 83–96.

17. Zhao, L.; Grob, S.; Corey, R.; Krupa, M.; Luo, J.; Du, H.; Lee, C.; Hughes, G.; Lee, J.; Quach, J.; et al. A novel compound heterozygous mutation in the BEST1 gene causes autosomal recessive Best vitelliform macular dystrophy. Eye 2012, 26, 866–871. [CrossRef]

18. Li, Y.; Zhang, Y.; Xu, Y.; Kittredge, A.; Ward, N.; Chen, S.; Tsang, S.H.; Yang, T. Patient-specific mutations impair BESTROPHIN1’s essential role in mediating Ca\(^{2+}\)-dependent Cl\(^-\) currents in human RPE. Elife 2017, 6, e29914. [CrossRef]

19. Tian, L.; Sun, T.; Xu, K.; Zhang, X.; Peng, X.; Li, Y. Screening of BEST1 Gene in a Chinese Cohort With Best Vitelliform Macular Dystrophy or Autosomal Recessive Bestrophinopathy. Investig. Ophthalmol. Vis. Sci. 2017, 58, 3366–3375. [CrossRef]

20. Kinnick, T.R.; Mullins, R.F.; Dev, S.; Leys, M.; Mackey, D.A.; Kay, C.N.; Lam, B.L.; Fishman, G.A.; Traboulsi, E.; Iezzi, R.; et al. Autosomal recessive vitelliform macular dystrophy in a large cohort of vitelliform macular dystrophy patients. Retina 2011, 31, 581–595. [CrossRef]

21. Bitner, H.; Mizrahi-Meissonnier, L.; Griefner, G.; Erdinest, I.; Sharon, D.; Banin, E. A homozygous frameshift mutation in BEST1 causes the classical form of Best disease in an autosomal recessive mode. Investig. Ophthalmol. Vis. Sci. 2011, 52, 5332–5338. [CrossRef] [PubMed]

22. Iannaccone, A.; Kerr, N.C.; Kinnick, T.R.; Calzada, J.I.; Stone, E.M. Autosomal recessive best vitelliform macular dystrophy: Report of a family and management of early-onset neovascular complications. Arch. Ophthalmol. 2011, 129, 211–217. [CrossRef] [PubMed]

23. Querques, G.; Bocco, M.C.; Soubrane, G.; Souied, E.H. Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy. Acta Ophthalmol. 2008, 86, 694–695. [CrossRef] [PubMed]